Vaccine Programs:

RSV

CDX-RSV to prevent RSV in the elderly

There is no approved vaccine against respiratory syncytial virus (RSV). Elderly patients infected with RSV typically have cold-like symptoms, but more serious infections lead to pneumonia and congestive heart failure. RSV vaccines have failed in the elderly in part because they have been unable to mount a robust cellular immune response. In animal models, Codagenix’s live-attenuated RSV vaccine not only works in subjects with pre-existing exposures to RSV, but also stimulates robust T cell activation.

Each Year in the US

177,000

Hospitalizations
Adults 65+

14,000 deaths

Adults 65+

Many people over the age of 65 already have antibodies against RSV from previous infections, but have very low levels of anti-RSV CD4 and CD8 T-cells. Only a live RSV vaccine can induce anti-RSV CD8 T-cells, shedding light on why multiple antigen-based vaccines have failed in the clinic. In preclinical studies, the Codagenix vaccine induces both potent cellular and antibody responses and works on subjects with pre-existing immunity against RSV. This combination of good vaccine “take” and induction of cellular immunity is the key to protecting people >55 years old from infections with RSV.

Patient resources